Cardiome -- CRME Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cardiome -- CRME

CRME 2.330

-2.1%

May 16 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: keokalani'nui who wrote (168)	7/25/2007 3:48:46 PM
From: tuck	Read Replies (1) of 285

K201: Competing program from NovaCardia, which is being mostly taken out by Merck. This program will be spun out into a separate entity, however . . . >>NovaCardia is developing K201 (JTV-519) for the treatment of A-Fib. We believe that K201 (JTV-519) has the potential to treat A-Fib without the side effects associated with current therapies, such as life-threatening ventricular arrhythmias. NovaCardia is developing IV and oral formulations of K201 (JTV-519) to address acute and chronic A-Fib, respectively. We plan to commence a Phase 2 clinical trial of the IV formulation of K201 (JTV-519) in 2007. The compound was licensed from Aetas Pharma Co., Ltd. in 2006.<< It's been around for a few years, and there's a fair amount of literature out there for the curious. Here's the most recent full text freebie: circ.ahajournals.org Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next